This roundtable series examines systemic therapies and other options approvedin those with steroid-refractorychronic graft-vs-host disease, as discussed by key opinion leaders and participants at virtual live events.
Biology Informs Treatment Options for Steroid-Refractory Chronic GVHDFebruary 22nd 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed biologic phases of chronic graft-vs-host disease and which therapies are available for patients who do not respond to steroids.
Using NCCN Guidelines for Chronic GVHD Therapy in Clinical PracticeMarch 9th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed 3 recommended agents for treatment of chronic graft-vs-host disease. This is the second of 2 articles based on this event.